Growth hormone-releasing factor analogue

Tesamorelin

FDA-approved - but for a much narrower goal than many online discussions imply.

Evidence Maturity · M5 for approved indication FDA-approved for HIV-associated lipodystrophy
Evidence reviewed: September 19, 2026Source-labeled

Signal summary

Tesamorelin is a flagship indication-boundary card: a drug can be fully approved and still not be approved for general weight-loss management.

Signal interpretation: This is one of the most important evidence-literacy examples on the site: 'FDA-approved' is not a universal stamp for every use people discuss online.

Study details

Doses studied — not a dosing recommendation. Regimens belong to the named study, formulation and population.

Pivotal HIV-lipodystrophy studies summarized in FDA labeling

Population
Adults with HIV-associated lipodystrophy and excess abdominal fat.
Doses and administration studied
Historical trials used tesamorelin 2 mg subcutaneously daily. Current product formulations are not automatically interchangeable with that historical trial dose.
Duration
26-week main studies, with extension follow-up
Reported finding / status
Two trials support abdominal-fat reduction and measured lean-mass increases, with minimal weight change, in HIV-associated lipodystrophy.
Interpretation and limitations
Not a general weight-loss indication. Long-term cardiovascular safety is not established. Consult the formulation-specific label for approved prescribing information.

Source tier A · Read the original study or record

Outcome Evidence Strength

Weight change4/5
Fat-mass change4/5
Lean-mass change4/5
Strength / function benefit0/5

Weight, fat and lean: replicated measurements in two indication-specific controlled studies; weight change was minimal. Function: benefit not established. These are not general weight-loss approval claims.

Editorial evidence ratings for the cited outcomes, not effect size or treatment recommendations. A lean-mass score may describe loss. 0 means not established in the reviewed evidence, not proof of no effect. Read the rubric.

What is actually established?

  • FDA labeling indicates tesamorelin for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy.
  • The current prescribing information explicitly says it is not indicated for weight-loss management.
  • Human trials support reductions in visceral adipose tissue in the approved population.

What is not established?

  • Approval for HIV-associated lipodystrophy does not establish general obesity treatment.
  • Body-composition findings in the approved population should not automatically be generalized to healthy adults or other populations.
  • Long-term cardiovascular safety is not established in the label.

Evidence sources

A = regulatory/official • B = peer-reviewed randomized/meta-analysis • C = peer-reviewed review/observational • D = registered trial • E = sponsor-reported • F = preclinical

Source tier A: FDA prescribing information
EGRIFTA WR prescribing information
Educational use only. This page summarizes research evidence and regulatory status. Study doses describe research, not prescribing instructions. This page does not provide personalized dosing, self-use protocols, sourcing, or a recommendation to use this therapy.